Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Division of Infectious Diseases, Rady Children's Hospital San Diego and the University of California San Diego School of Medicine, San Diego, California, USA.
Clin Infect Dis. 2022 Oct 17;75(Suppl 3):S341-S353. doi: 10.1093/cid/ciac534.
Anthrax is a toxin-mediated zoonotic disease caused by Bacillus anthracis, with a worldwide distribution recognized for millennia. Bacillus anthracis is considered a potential biowarfare agent.
We completed a systematic review for clinical and demographic characteristics of adults and children hospitalized with anthrax (cutaneous, inhalation, ingestion, injection [from contaminated heroin], primary meningitis) abstracted from published case reports, case series, and line lists in English from 1880 through 2018, assessing treatment impact by type and severity of disease. We analyzed geographic distribution, route of infection, exposure to anthrax, and incubation period.
Data on 764 adults and 167 children were reviewed. Most cases reported for 1880 through 1915 were from Europe; those for 1916 through 1950 were from North America; and from 1951 on, cases were from Asia. Cutaneous was the most common form of anthrax for all populations. Since 1960, adult anthrax mortality has ranged from 31% for cutaneous to 90% for primary meningitis. Median incubation periods ranged from 1 day (interquartile range [IQR], 0-4) for injection to 7 days (IQR, 4-9) for inhalation anthrax. Most patients with inhalation anthrax developed pleural effusions and more than half with ingestion anthrax developed ascites. Treatment and critical care advances have improved survival for those with systemic symptoms, from approximately 30% in those untreated to approximately 70% in those receiving antimicrobials or antiserum/antitoxin.
This review provides an improved evidence base for both clinical care of individual anthrax patients and public health planning for wide-area aerosol releases of B. anthracis spores.
炭疽是一种由炭疽杆菌引起的毒素介导的人畜共患病,其分布范围在全球范围内已有数千年的历史。炭疽杆菌被认为是一种潜在的生物战剂。
我们从 1880 年至 2018 年期间以英文发表的病例报告、病例系列和病例清单中,系统地回顾了成年人和儿童因炭疽(皮肤、吸入、摄入、注射[来自受污染的海洛因]、原发性脑膜炎)住院的临床和人口统计学特征,评估了不同疾病类型和严重程度的治疗效果。我们分析了地理分布、感染途径、炭疽接触和潜伏期。
共回顾了 764 名成年人和 167 名儿童的数据。1880 年至 1915 年报告的大多数病例来自欧洲;1916 年至 1950 年的病例来自北美;从 1951 年开始,病例来自亚洲。皮肤炭疽是所有人群中最常见的炭疽形式。自 1960 年以来,成人炭疽死亡率从皮肤炭疽的 31%到原发性脑膜炎的 90%不等。潜伏期中位数范围从注射的 1 天(四分位距[IQR],0-4)到吸入炭疽的 7 天(IQR,4-9)。大多数吸入性炭疽患者出现胸腔积液,超过一半的摄入性炭疽患者出现腹水。治疗和重症监护的进步提高了有全身症状患者的生存率,从未接受治疗的患者的约 30%提高到接受抗生素或抗血清/抗毒素的患者的约 70%。
本综述为炭疽患者的临床护理以及针对炭疽杆菌孢子大面积气溶胶释放的公共卫生规划提供了更好的证据基础。